[Abstract Only] Randomized Trial: Four Cycles of R-CHOP Non-inferior to Six Cycles of R-CHOP in Patients with Aggressive B-cell non-Hodgkin Lymphoma and Favorable Prognosis

Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis (FLYER): a randomised, phase 3, non-inferiority trial – The Lancet (link to abstract – $ for full-text)

Related Commentary on Twitter

Four cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis (FLYER): The new standard of care for limited DLBCL with favorable prognosis https://t.co/oAH9dJJGZA

— Georgios Pongas, MD (@pongasg) December 24, 2019